Impact of CD22 CAR T-cell therapy on leukemia cell transcriptome

Although CD19 CAR T therapy has attained encouraging clinical outcomes worldwide, leukemia relapse after this therapy is associated with particular poor prognosis and has become an urgent problem to be solved. In consideration of the possible genetic or transcriptomic mechanisms underlying relapse, leukemia samples before CAR T cell infusion and after relapse were subjected to transcriptome sequencing Two B-ALL samples from the same patient, collected respectively at his pre-treatment stage and after the tumor relapse